Floatz logo

Pazopanib

Nonpapillary Renal Cell Carcinoma

Academic and Community Cancer Research UnitedSmall moleculePhase 4 / ApprovedActive
BB
66/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
62/ 100
Competitive Position
73/ 100

Competitive context

111 Active assets in the Nonpapillary Renal Cell Carcinoma cohort.

Asset / SponsorPhaseRating
Girentuximab
Massachusetts General Hospital
Phase 3BB
CLOSTRIDIUM BUTYRICUM MIYAIRI 588
City of Hope Medical Center
Phase 3BB
IMMUNOGLOBULIN G4, ANTI-(HUMAN PROGRAMMED CELL DEATH PROTEIN 1) (HUMAN MONOCLONAL REGN2810 HEAVY CHAIN), DISULFIDE WITH HUMAN MONOCLONAL REGN2810 .KAPPA.-CHAIN, DIMER
Regeneron Pharmaceuticals
Phase 2BB
Cabozantinib
SWOG Cancer Research Network
Phase 3BB
Nivolumab
Fred Hutchinson Cancer Center
Phase 3BB

View all 50 →

Same molecule, other indications

Pazopanib is also rated in:

renal cell carcinomaActive
BBB
Indicative · Phase 4
79 / 100
View asset →
ovarian neoplasmDormant
BB
Indicative · Phase 2
71 / 100
View asset →
non-small cell lung carcinomaDormant
BB
Indicative · Phase 2/3
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →